Skip to main content
SpringerLink
Log in

Mean platelet volume in patients with fibromyalgia

Mittleres Thrombozytenvolumen bei Patienten mit Fibromyalgie

  • Originalien
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Abstract

Fibromyalgia is a syndrome characterised by chronic widespread pain at multiple tender points, as well as joint stiffness and systemic symptoms. The aetiology and pathogenesis of fibromyalgia still remain unclear, although many contributory factors have been suggested. The presence of some common features between fibromyalgia and cardiovascular risk factors (e.g. depression and sleep disturbance) led to question of whether there is there a relationship between fibromyalgia and cardiovascular disease and/or atherosclerosis. Mean platelet volume, which is a determinant of platelet activation, is a newly emerging independent risk factor for cardiovascular disease.

The present study was designed to evaluate levels of mean platelet volume in patients with fibromyalgia; the study population consisted of 283 individuals with this syndrome, who were compared with 72 healthy controls. Erythrocyte sedimentation rate, C-reactive protein, white blood cell count, platelet count and mean platelet volume levels were retrospectively recorded via the computerised patient database. The levels of mean platelet volume were significantly higher in the fibromyalgia group than in the control group (8.09 ± 0.84 fl and 7.73 ± 0.65 fl, respectively, p < 0.001). There were no statistical differences between groups with regard to platelet count and other parameters. These results suggest that an early atherosclerosis marker, mean platelet volume, is elevated in patients with fibromyalgia. This indicates increased platelet activation and therefore a higher risk of future cardiovascular disease.

Zusammenfassung

Fibromyalgie ist ein Syndrom, das durch chronische, an mehreren Tenderpoints verbreitete Schmerzen sowie durch Gelenksteife und systemische Symptome gekennzeichnet ist. Ätiologie und Pathogenese der Fibromyalgie sind immer noch ungeklärt, auch wenn viele mitwirkende Faktoren genannt worden sind. Das Vorliegen einiger gemeinsamer Merkmale von Fibromyalgie und kardiovaskulären Risikofaktoren (z. B. Depression und Schlafstörungen) führte zu der Frage, ob es einen Zusammenhang zwischen Fibromyalgie und Herz-Kreislauf-Erkrankungen und/oder Atherosklerose gebe. Das mittlere Thrombozytenvolumen, ein Parameter der Thromobozytenaktivierung, ist ein neu aufkommender unabhängiger Risikofaktor für Herz-Kreislauf-Erkrankungen.

Mit der vorliegenden Studie sollte die Höhe des mittleren Thrombozytenvolumens bei Patienten mit Fibromyalgie ermittelt werden; die Studienpopulation bestand aus 283 Personen mit diesem Syndrom, welche mit 72 gesunden Kontrollen verglichen wurden. Blutsenkungsgeschwindigkeit, C-reaktives Protein, Leukozytenzahl, Thrombozytenzahl und mittleres Thrombozytenvolumen wurden retrospektiv anhand der elektronischen Patientendatenbank erfasst. Die Werte für das mittlere Thrombozytenvolumen waren in der Gruppe mit Fibromyalgie signifikant höher als in der Kontrollgruppe (8,09 ± 0,84 fl bzw. 7,73 ± 0,65 fl; p < 0,001). Es gab keine statistischen Unterschiede zwischen den Gruppen in Hinblick auf die Thrombozytenzahl und andere Parameter. Diese Ergebnisse sprechen dafür, dass ein früher Atherosklerosemarker, das mittlere Thrombozytenvolumen, bei Patienten mit Fibromyalgie erhöht ist. Das ist ein Anzeichen einer erhöhten Thrombozytenaktivierung und somit eines höheren Risikos zukünftiger Herz-Kreislauf-Erkrankungen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bigatti SM, Hernandez AM, Cronan TA, Rand KL (2008) Sleep disturbances infibromyalgia syndrome: relationship to pain and depression. Arthritis Care Res 59(7):961–967

    Article  Google Scholar 

  2. Clauw DJ (2009) Fibromyalgia: an overview. Am J Med 122(12):3–13

    Article  Google Scholar 

  3. Bellato E, Marini E, Castoldi F et al (2012) Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat. doi:10.1155/2012/426130

  4. Smith HS, Harris R, Clauw D (2011) Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 14(2):217–245

    Google Scholar 

  5. Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172

    Article  PubMed  CAS  Google Scholar 

  6. Wolfe F (2010) New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res 62(5):583–584

    Article  Google Scholar 

  7. Wolfe F, Clauw DJ, Fitzcharles MA et al (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62(5):600–610

    Article  Google Scholar 

  8. Assumpção A, Cavalcante AB, Capela CE et al (2009) Prevalence of fibromyalgia in a low socioeconomic status population. BMC Musculoskelet Disord 10:64

    Article  PubMed  PubMed Central  Google Scholar 

  9. Branco JC, Bannwarth B, Failde I et al (2010) Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 39(6):448–453

    Article  PubMed  Google Scholar 

  10. Rozanski A (2005) Integrating psychologic approaches into the behavioral management of cardiac patients. Psychosom Med 67(Suppl 1):S67–S73

    Article  PubMed  Google Scholar 

  11. Miller MA (2011) Association of inflammatory markers with cardiovascular risk and sleepiness. J Clin Sleep Med 7(5 Suppl):S31–S33

    PubMed  PubMed Central  Google Scholar 

  12. Yılmaz H, Ertugrul O, Ertugrul B, Ertugrul D (2011) Mean platelet volume in patients with subclinical hypothyroidism. Platelets 22(2):143–147

    Article  PubMed  Google Scholar 

  13. Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG (2011) High platelet volume and increased risk of myocardial infarction: 39531 participants from the general population. J Thromb Haemost 9:49–56

    Article  PubMed  CAS  Google Scholar 

  14. Kosus N, Kosus A, Turhan NO (2011) Relationship of ovarian volume with mean platelet volume and lipid profile in patients with polycystic ovary syndrome. Exp Ther Med 2:1141–1144

    PubMed  CAS  PubMed Central  Google Scholar 

  15. Martin JF, Trowbridge EA, Salmon G, Plumb J (1983) The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1:443–460

    Article  Google Scholar 

  16. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 17:47–58

    Article  PubMed  CAS  Google Scholar 

  17. Bavbek N, Kargili A, Kaftan O et al (2007) Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy? Clin Appl Thromb Hemost 13:391–397

    Article  PubMed  CAS  Google Scholar 

  18. Makay B, Turkyilmaz Z, Unsal E (2009) Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 28:975–978

    Article  PubMed  Google Scholar 

  19. Thompson CB (1986) From precursor to product: how do megakaryocytes produce platelets? Prog Clin Biol Res 215:361–371

    PubMed  CAS  Google Scholar 

  20. Thompson CB, Jakubowski JA (1988) The pathophysiology and clinical relevance of platelet heterogeneity. Blood 72:1–8

    PubMed  CAS  Google Scholar 

  21. Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339–3347

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Miyazaki H, Kato T (1999) Thrombopoietin: biology and clinical potentials. Int J Hematol 70:216–225

    PubMed  CAS  Google Scholar 

  23. Butkiewicz AM, Kemona-Chetnik I, Dymicka-Piekarska V et al (2006) Does smoking affect thrombocytopoiesis and platelet activation in women and men? Adv Med Sci 51:123–126

    PubMed  CAS  Google Scholar 

  24. Tavil Y, Sen N, Yazici HU et al (2007) Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 120:245–250

    Article  PubMed  CAS  Google Scholar 

  25. Mitchell MD, Mannino DM, Steinke DT et al (2011) Association of smoking and chronic pain syndromes in Kentucky women. J Pain 12(8):892–899

    Article  PubMed  Google Scholar 

  26. Cordero MD, Alcocer-Gómez E, Cano-García FJ et al (2013) Clinical symptoms in fibromyalgia are associated to overweight and lipid profile. Rheumatol Int. doi:10.1007/s00296-012-2647-2

  27. Arranz L, Angel Canela M, Rafecas M (2012) Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients. Rheumatol Int 32:3605–3611

    Article  PubMed  Google Scholar 

  28. Jahan F, Nanji K, Qidwai W, Qasim R (2012) Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. Oman Med J 27:192–195

    Article  PubMed  PubMed Central  Google Scholar 

  29. Thompson CB, Eaton KA, Princiotta SM et al (1982) Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 50:509–519

    Article  PubMed  CAS  Google Scholar 

  30. Vizioli L, Muscari S, Muscari A (2009) The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 63:1509–1515

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with ethical guidelines

Conflict of interest. S. Haliloğlu, A. Carlioglu, E. Sahiner, Y. Karaaslan, and A. Kosar state that there are no conficts of interest. The accompanying manuscript does not include studies on humans or animals.

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Erzurum Regional Research and Training Hospital, 25240, Erzurum, Turkey

    S. Haliloğlu

  2. Department of Endocrinology, Erzurum Regional Research and Training Hospital, Erzurum, Turkey

    A. Carlioglu

  3. Department of Internal Medicine, Faculty of Medicine, Fatih University, Ankara, Turkey

    E. Sahiner

  4. Department of Rheumatology, Ankara Numune Research and Training Hospital, Ankara, Turkey

    Y. Karaaslan

  5. Department of Hematology, Faculty of Medicine, Fatih University, Ankara, Turkey

    A. Kosar

Authors
  1. S. Haliloğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Carlioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Sahiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Karaaslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Kosar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Haliloğlu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haliloğlu, S., Carlioglu, A., Sahiner, E. et al. Mean platelet volume in patients with fibromyalgia. Z. Rheumatol. 73, 742–745 (2014). https://doi.org/10.1007/s00393-013-1330-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-013-1330-7

Keywords

Schlüsselwörter

Search

Navigation